previous aducanumab trials access medication explaining results trials called emerge positive conference budd haeberlein said 29 percent patients emerge 22 percent patients trial engage received regimen 14 doses 10 milligrams kilogram weight trials started late summer 2015 patients followed 18 months march decision discontinue studies biogen combined emerge engage data cut results december 2018 meaning fewer people completed dose regimen aducanumab positive results diluted budd haeberlein said patients gene called dramatically increases risk alzheimer saw improvements emerge data effects drug manageable budd haeberlein expert panel said eric reiman executive director banner alzheimer institute research organization notes findings trials not definitive